Tag: Drug shortage

Following the U.S. Food and Drug Administration's (FDA) declaration in late 2024 that the national tirzepatide shortage was resolved, a wave of confusion and misinformation has circulated regarding the medication's status. It is crucial to clarify that the FDA is **not removing tirzepatide** from the market; instead, it has ceased the temporary allowance for compounding pharmacies to produce non-FDA-approved versions of the drug. This regulatory shift impacts patients using compounded products, requiring them to transition to the brand-name alternatives, Mounjaro and Zepbound.

As of September 2025, the American Society of Health-System Pharmacists (ASHP) reported over 270 active drug shortages, a persistent problem in the US healthcare system. This ongoing crisis leaves many patients wondering: **What drug is currently in shortage in 2025?** and how will it affect my treatment?

Following a period of significant and widespread shortages, the U.S. Food and Drug Administration (FDA) officially declared the national shortage of the active ingredient tirzepatide over in December 2024. This offers much-needed clarity for those asking: **Does Zepbound have supply issues?**

Over the last century, a significant number of drugs have been voluntarily withdrawn by manufacturers or mandated by regulatory agencies, primarily due to adverse drug reactions and other safety issues. Understanding why a medication is no longer available is crucial for patient safety, as many factors beyond a safety recall can influence which medications are discontinued.

While the U.S. Food and Drug Administration (FDA) declared the national shortage of the active ingredient in Zepbound resolved in late 2024, real-time availability can still fluctuate at the local pharmacy level. Patients must be persistent to ensure is Zepbound readily available at pharmacies, especially with recent changes impacting insurance coverage and compounded alternatives.

The U.S. Food and Drug Administration (FDA) officially declared the shortage of Zepbound and its active ingredient, tirzepatide, resolved in December 2024 after manufacturer Eli Lilly ramped up production. However, throughout the year, many patients have continued to experience intermittent access issues, leading to persistent questions: **Is there a Zepbound shortage in 2025?**.

According to data from IQVIA, the number of prescriptions for popular GLP-1 medications, like Zepbound and Wegovy, quadrupled over two years, creating unprecedented demand. This surge, combined with numerous supply chain and market factors, explains why many patients still find it so hard to get Zepbound at their local pharmacy.

As of March 19, 2025, the landscape for tirzepatide users has fundamentally changed [1.2.1, 1.2.3]. The question on many minds is: **is compounded tirzepatide really going away?** The short answer is yes, due to decisive action from the U.S. Food and Drug Administration (FDA).

While compounded semaglutide contains the same active ingredient as FDA-approved versions, it is not an identical or equivalent product. Its quality, safety, and effectiveness are not subject to the rigorous testing and review mandated by the FDA for branded medications like Ozempic and Wegovy.

Over 90% of glaucoma cases are the open-angle type, for which timolol is a common treatment [1.9.1]. The question of 'Is timolol out of stock?' has become a significant concern for many who rely on it to prevent irreversible vision loss [1.9.2].